This article compares two approaches side by side to clarify how they differ in principle and practice. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding.
Microwave ablation (MWA) vs Radiofrequency ablation (RFA): Key Differences
Both microwave and radiofrequency ablation are heat-based techniques that aim to coagulate a tumor in place, and both are widely used percutaneously under image guidance. MWA is often described as achieving higher intratumoral temperatures more quickly and as being less affected by the heat-sink effect near large vessels, while RFA has an especially deep evidence base in HCC. RFA systems typically rely on tissue impedance and electrode cooling, whereas MWA depends on antenna and generator characteristics, so the practical trade-offs differ by lesion. There is no universally superior modality; the treating physician selects between them based on tumor size, location, and proximity to critical structures.
How INVAMED Supports Both Approaches
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). For intravesical therapy, the HyperTiss Intracavitary Hypothermia Set is positioned for adjunctive use alongside intravesical chemotherapy in bladder cancer. Generator specifications, applicator and antenna options, and compatible accessories are provided in product documentation, and buyers should request the relevant IFU for each variant.
Key Considerations
- Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
Frequently Asked Questions
Is the HyperTiss set an ablation device?
INVAMED describes HyperTiss as an intracavitary (intravesical) temperature-therapy set intended for adjunctive use with intravesical chemotherapy in bladder cancer, rather than as a standalone tumor ablation device.
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
INVAMED's Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors is positioned specifically for intraosseous RF delivery in vertebral and spinal tumor ablation. INVAMED's HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment is an intravesical temperature-therapy set positioned for adjunctive use alongside intravesical chemotherapy for bladder cancer. Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use. Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
Related on INVAMED
- Oncology Ablation — product category
- Ablation or Surgical resection? A Technical Comparison
- A Clinical Introduction to Laser Trans-Urethral Ablation
- Understanding Percutaneous Thermal Ablation Electrodes
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.